CELLULOSIC-BASED INTERFERENCE DOMAIN FOR AN ANALYTE SENSOR

  • US 20100121169A1
  • Filed: 01/21/2010
  • Published: 05/13/2010
  • Est. Priority Date: 04/08/2005
  • Status: Abandoned Application
  • ×
    • Pin Icon | RPX Insight
    • Pin
First Claim
Patent Images

1. An implantable device for continuous in vivo measurement of a glucose concentration in a host, the implantable device comprising:

  • a sensing region operatively connected to electronic circuitry configured to continuously generate, over a period of at least about 3 days, a signal associated with an in vivo concentration of glucose in a host; and

    a membrane located over the sensing region, wherein the membrane comprises a first domain configured to control a flux of glucose and oxygen therethrough, a second domain comprising an enzyme configured to react with glucose, and a third domain configured to substantially reduce a flux of at least one interferent therethrough, wherein the third domain comprises at least one cellulosic derivative;

    wherein the implantable device is configured to reduce, while immersed in a solution with an acetaminophen concentration of about 6.5 mg/dL, an equivalent glucose response signal associated with acetaminophen to less than about 30 mg/dL.

View all claims
  • 2 Assignments